Ramon da Costa Saavedra

Dr. Ramon da Costa Saavedra

orcid

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
23 May 2024 in The Lancet Regional Health - Americas
Verified
Journal Article
Open access
RSRita Carvalho Sauer
Rita Carvalho Sauer
MCMaria da Conceição Nascimento Costa
Maria da Conceição Nascimento Costa
MTMaria Glória Teixeira
Maria Glória Teixeira
RFRenzo Flores-Ortiz
Renzo Flores-Ortiz
JLJessidenes Teixeira de Freitas Mendes Leal
Jessidenes Teixeira de Freitas Mendes Leal
EPEnny S. Paixão
Enny S. Paixão
Few studies have evaluated the effects of the Coronavirus disease 2019 (COVID-19) pandemic, caused by the SARS-CoV-2 virus, on maternal and perinatal health at a populational level. We investigated maternal and perinatal health indicators in Brazil, focusing on the effects of the COVID-19 pandemic, and SARS-CoV-2 vaccination campaign for pregnant women. Utilizing interrupted time series analysis (January 2013-December 2022), we examined Maternal Mortality Ratio, Perinatal Mortality Rate, Preterm Birth Rate, Cesarean Section Rate, and other five indicators. Interruptions occurred at the pandemic's onset (March 2020) and pregnant women's vaccination (July 2021). Results were expressed as percent changes on time series' level and slope. The COVID-19 onset led to immediate spikes in Maternal Mortality Ratio (33.37%) and Perinatal Mortality Rate (3.20%) (p < 0.05). From March 2020 to December 2022, Cesarean Section and Preterm Birth Rates exhibited upward trends, growing monthly at 0.13% and 0.23%, respectively (p < 0.05). Post start of SARS-CoV-2 vaccination (July 2021), Maternal Mortality Ratio (-34.10%) and Cesarean Section Rate (-1.87%) promptly declined (p < 0.05). Subsequently, we observed a monthly decrease of Maternal Mortality Ratio (-9.43%) and increase of Cesarean Section Rate (0.25%) (p < 0.05), while Perinatal Mortality Rate and Preterm Birth Rate showed a stationary pattern. The pandemic worsened all analyzed health indicators. Despite improvements in Maternal Mortality Ratio, following the SARS-CoV-2 vaccination campaign for pregnant women, the other indicators continued to sustain altered patterns from the pre-pandemic period. No funding.

15 May 2025 in Vaccines
Verified
Journal Article
Open access
PDF file
RSRamon da Costa Saavedra
Ramon da Costa Saavedra
RSRita Carvalho Sauer
Rita Carvalho Sauer
EPEnny S. Paixão
Enny S. Paixão
MIMaria Yury Travassos Ichihara
Maria Yury Travassos Ichihara
MCMaria da Conceição Nascimento Costa
Maria da Conceição Nascimento Costa
MTMaria Glória Teixeira
Maria Glória Teixeira
Background: The COVID-19 pandemic had significant impacts on healthcare systems, including the disruption of essential services such as childhood immunization. Containment measures, such as social distancing, contributed to reduced adherence to vaccination programs, increasing the risk of re-emerging vaccine-preventable diseases. We aim to assess the evolution of childhood vaccination coverage in Brazil from 2010 to 2024, identifying trends before, during, and after the COVID-19 pandemic. Methods: An interrupted time series (ITS) study was conducted using publicly available aggregated data on vaccination coverage for children under one year of age. Prais–Winsten regression models were applied to estimate trend changes and evaluate the impact of the pandemic on immunization levels. Results: The findings indicate a progressive decline in vaccination coverage between 2010 and 2019, which was intensified in 2020 by the pandemic. The BCG vaccine showed the greatest decline (−24.88%, p < 0.001), while pentavalent and hepatitis B vaccines decreased annually by −3.72% and −2.21%, respectively. From 2021 onwards, a gradual recovery in coverage was observed, with significant increases for BCG (+7.48% per year, p < 0.001), hepatitis B (+7.45%, p = 0.014), and MMR (+6.73%, p = 0.017) vaccines. Discussion: The results highlight a concerning decline in childhood immunization, exacerbated by the pandemic but showing recent signs of recovery. This scenario underscores structural challenges within the National Immunization Program, requiring coordinated efforts to reverse vaccination losses and ensure system resilience in the face of future crises.

5 May 2023 in BMC Pregnancy and Childbirth
Verified
Journal Article
Open access
PDF file
RSRita Carvalho Sauer
Rita Carvalho Sauer
RFRenzo Flores-Ortiz
Renzo Flores-Ortiz
MCMaria da Conceição Nascimento Costa
Maria da Conceição Nascimento Costa
MTMaria Glória Teixeira
Maria Glória Teixeira
RSRamon da Costa Saavedra
Ramon da Costa Saavedra
EPEnny S. Paixão
Enny S. Paixão
Background: Fetal loss is one of the most serious adverse outcomes of pregnancy. Since the onset of the COVID-19 pandemic, Brazil has recorded an unprecedented number of hospitalizations of pregnant women due to acute respiratory distress (ARD), thereby, we aimed to assess the risk of fetal deaths associated to ARD during pregnancy in Bahia state, Brazil, in the context of the COVID-19 pandemic.Methods: This is an observational population-based retrospective cohort study, developed with women at or after 20 weeks of pregnancy, residents in Bahia, Brazil. Women who had acute respiratory distress (ARD) in pregnancy during the COVID-19 pandemic (Jan 2020 to Jun 2021) were considered 'exposed'. Women who did not have ARD in pregnancy, and whose pregnancy occurred before the onset of the COVID-19 pandemic (Jan 2019 to Dec 2019) were considered 'non-exposed'. The main outcome was fetal death. We linked administrative data (under mandatory registration) on live births, fetal deaths, and acute respiratory syndrome, using a probabilistic linkage method, and analyzed them with multivariable logistic regression models.Results: 200,979 pregnant women participated in this study, 765 exposed and 200,214 unexposed. We found four times higher chance of fetal death in women with ARD during pregnancy, of all etiologies (adjusted odds ratio [aOR] 4.06 confidence interval [CI] 95% 2.66; 6.21), and due to SARS-CoV-2 (aOR 4.45 CI 95% 2.41; 8.20). The risk of fetal death increased more when ARD in pregnancy was accompanied by vaginal delivery (aOR 7.06 CI 95% 4.21; 11.83), or admission to Intensive Care Unit (aOR 8.79 CI 95% 4.96; 15.58), or use of invasive mechanical ventilation (aOR 21.22 CI 95% 9.93; 45.36).Conclusion: Our findings can contribute to expanding the understanding of health professionals and managers about the harmful effects of SARS-CoV-2 on maternal–fetal health and alerts the need to prioritize pregnant women in preventive actions against SARS-CoV-2 and other respiratory viruses. It also suggests that pregnant women, infected with SARS-CoV-2, need to be monitored to prevent complications of ARD, including a careful assessment of the risks and benefits of early delivery to prevent fetal death.

1 January 2024 in Epidemiologia e Serviços de Saúde
Verified
Journal Article
Open access
PDF file
RSRamon da Costa Saavedra
Ramon da Costa Saavedra
MSMartha Suely Itaparica de Carvalho Santiago
Martha Suely Itaparica de Carvalho Santiago
MTMaria Glória Teixeira
Maria Glória Teixeira
MAMaria Bernadete de Cerqueira Antunes
Maria Bernadete de Cerqueira Antunes
RQRejane Christine de Sousa Queiroz
Rejane Christine de Sousa Queiroz
Wildo AraujoWildo Araujo
Wildo Araujo
Objective To estimate vaccination coverage and analyze sociodemographic factors associated with non-vaccination in children born in 2017 and 2018 in the state capitals of Northeast Brazil. Methods A household survey using cluster sampling was conducted from 2020-2022 to estimate vaccination coverage and hesitancy. Factors associated with non-vaccination were analyzed using logistic regression to calculate Odds Ratios (OR) and their Confidence Intervals (95%CI). Results Natal was the capital with the lowest vaccination coverage, below 75.0% for most immunizers. Teresina had rates equal to or greater than 90.0% for all vaccines. Among those interviewed, 99.1% (95%CI 98.9;99.3) believe that vaccines are important for health; 95.4% (95%CI 95.0;95.8) trust immunobiologicals and 79.6% (95%CI% 78.8;80.3) are not afraid of reactions. Belonging to the highest socioeconomic stratum (adjusted OR: 1.34 – 95%CI 1.20;1.50) was as a factor associated with non-vaccination. Conclusion Low coverage highlights the need for a better understanding of regional specificities and social inequalities.

1 January 2024 in Epidemiologia e Serviços de Saúde
Verified
Journal Article
Open access
PDF file
AFAnderson Fuentes Ferreira
Anderson Fuentes Ferreira
Alberto Novaes Ramos Jr.Alberto Novaes Ramos Jr.
Alberto Novaes Ramos Jr.
AMAdjoane Mauricio Silva Maciel
Adjoane Mauricio Silva Maciel
JBJaqueline Caracas Barbosa
Jaqueline Caracas Barbosa
RSRamon da Costa Saavedra
Ramon da Costa Saavedra
Wildo AraujoWildo Araujo
Wildo Araujo
Objective To analyze vaccination coverage and factors associated with incomplete vaccination in inland municipalities of Northeastern Brazil.

7 February 2025 in Vaccines
Verified
Journal Article
Open access
PDF file
RSRamon da Costa Saavedra
Ramon da Costa Saavedra
EPEnny S. Paixão
Enny S. Paixão
MIMaria Yury Travassos Ichihara
Maria Yury Travassos Ichihara
MCMaria da Conceição Nascimento Costa
Maria da Conceição Nascimento Costa
RSRita Carvalho Sauer
Rita Carvalho Sauer
MTMaria Glória Teixeira
Maria Glória Teixeira
Background: Despite adverse events following immunization (AEFI) being well described in vaccine trials, there is a need to produce more real-world data on events supposedly attributed to vaccination against COVID-19. This study aims to estimate the prevalence of AEFI in the first dose of COVID-19 vaccines in the state of Brazil and to verify whether such events differ among the types of vaccines offered in this country. Methods: A population-based study using linked administrative data on vaccine registry and adverse events following immunization in 2021 and 2022. The study included 10,169,378 individuals aged 18 or over who lived in Bahia and received the first dose of COVID-19 vaccines. We calculated AEFI prevalence and verified differences among vaccines by logistic regression to estimate crude and adjusted by sex and age group prevalence ratio (PR). Results: The prevalence of AEFI was 74.3 per 100,000 doses applied, with a higher rate of nonserious events, mainly following the ChAdOx1-S. More than two-thirds of these adverse effects occurred in women, and almost half were between 30 and 49 years old. The individuals who received ChAdOx1-S had a 125% higher prevalence than those who received CoronaVac. Those who received BNT162b2 and Ad26.COV2.S had a 71% and 58%, respectively, lower prevalence of AEFI than those who received CoronaVac. Conclusions: The use of vaccines against COVID-19 has proven to be positive and effective in combating SARS-CoV-2, significantly reducing morbidity and mortality from the disease. We cannot deny the presence of adverse events in the context of vaccination. However, the vaccines have proven to be safe and reliable. The results of this study offer relevant data that can contribute to the qualification of AEFI pharmacovigilance in Brazil and worldwide.